Intuitive surgical director Amy Ladd sells $179,903 in company stock By Investing.com

Amy L. Ladd, a director at Intuitive Surgical Inc. (), recently sold shares of the company’s common stock totaling $179,903. The transactions occurred over two days in August 2026.

On August 10, 2026, Ms. Ladd disposed of 400 shares, followed by the sale of an additional 72 shares on August 11, 2026. The shares were sold at prices ranging from $379.00 to $393.10. These sales were conducted under a pre-arranged trading plan that complies with SEC Rule 10b5-1 and is set to expire on May 15, 2027.

Following these transactions, Ms. Ladd directly holds 179 shares of Intuitive Surgical common stock. For investors seeking deeper insights into ISRG’s valuation and performance metrics, InvestingPro offers comprehensive Pro Research Reports covering this and 1,400+ other US equities, transforming complex Wall Street data into clear, actionable intelligence.

In other recent news, Intuitive Surgical Inc. reported impressive second-quarter results with earnings per share reaching $2.80, surpassing analyst expectations of $2.51. The company achieved a 19% increase in revenue, totaling $2.89 billion, which exceeded estimates of $2.82 billion. Instruments and accessories sales rose by 18%, while systems sales increased by 19%, with 468 da Vinci shipments, beating the consensus of 444. Despite these strong financial results, the company’s full-year procedure growth guidance raised concerns among investors, leading to a notable decline in share value.

In terms of analyst actions, UBS initiated coverage of Intuitive Surgical with a buy rating and a price target of $500, citing the company’s leadership in medical technology. Meanwhile, Bernstein SocGen Group adjusted its price target to $685 from $750, maintaining an Outperform rating due to concerns about U.S. growth. BMO Capital reiterated an Outperform rating with a $518 price target following the quarterly results.

Stifel also lowered its price target from $670 to $550, maintaining a Buy rating, while noting management’s uncertainty about future growth. These developments highlight the mixed sentiment among analysts regarding Intuitive Surgical’s future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.